The NuVasive Board of Directors strongly urges NuVasive shareholders to vote FOR all the
NuVasive proposals set forth in the definitive proxy statement for the NuVasive special meeting, including FOR the proposal to adopt the merger agreement with Globus Medical.
NuVasive shareholders who have questions or need assistance in voting their shares should contact NuVasives proxy solicitor, Innisfree M&A
Incorporated, by calling toll-free at (877) 687-1873 (U.S. or Canada) or +1 (412) 232-3651 (international).
The merger of NuVasive and Globus Medical is expected to close in the middle of 2023, subject to the approval of both companies shareholders, regulatory
approval, and other customer closing conditions.
About NuVasive
NuVasive, Inc. (NASDAQ: NUVA) is the leader in spine technology innovation, with a mission to transform surgery, advance care, and change lives. The
Companys less-invasive, procedurally integrated surgical solutions are designed to deliver reproducible and clinically proven outcomes. The Companys comprehensive procedural portfolio includes surgical access instruments, spinal
implants, fixation systems, biologics, software for surgical planning, navigation and imaging solutions, magnetically adjustable implant systems for spine and orthopedics, and intraoperative neuromonitoring technology and service offerings. With
more than $1 billion in net sales, NuVasive operates in more than 50 countries serving surgeons, hospitals, and patients. For more information, please visit www.nuvasive.com.
Cautionary Notes on Forward-Looking Statements
This
communication contains forward-looking statements within the meaning of the federal securities laws, including Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as
amended. In this context, forward-looking statements often address expected future business and financial performance and financial condition, and often contain words such as expect, anticipate, intend,
plan, believe, seek, see, will, would, may, target, and similar expressions and variations or negatives of these words. Forward-looking statements by
their nature address matters that are, to different degrees, uncertain, such as statements about the consummation of the proposed transaction and the anticipated benefits thereof. These and other forward-looking statements are not guarantees of
future results and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially from those expressed in any forward-looking statements, including the failure to consummate the proposed transaction or to
make any filing or take other action required to consummate such transaction in a timely matter or at all. Important risk factors that may cause such a difference include, but are not limited to: (i) the proposed transaction may not be
completed on anticipated terms and timing or at all, (ii) a condition to closing of the transaction may not be satisfied, including obtaining shareholder and regulatory approvals, (iii) the anticipated tax treatment of the transaction may
not be obtained, (iv) the potential impact of unforeseen liabilities, future capital expenditures, revenues, costs, expenses, earnings, synergies, economic performance, indebtedness, financial condition and losses on the future prospects,
business and management strategies for the management, expansion and growth of the combined business after the consummation of the transactions, (v) potential litigation relating to the proposed transaction that could be instituted against
Globus Medical, NuVasive or their respective directors, (vi) potential adverse reactions or changes to business relationships resulting from the announcement or completion of the transactions, (vii) any negative effects of the
announcement, pendency or consummation of the transactions on the market price of Globus Medicals or NuVasives common stock and on Globus Medicals or NuVasives businesses or operating results, (viii) risks associated
with third party contracts containing consent and/or other provisions that may be triggered by the proposed transaction, (ix) the risks and costs associated with the integration of, and the ability of Globus Medical and NuVasive to integrate,
their businesses successfully and to achieve anticipated synergies, (x) the risk that disruptions from the proposed transaction will harm Globus Medicals or NuVasives business, including current plans and operations, (xi) the
ability of Globus Medical or NuVasive to retain and hire key personnel and uncertainties arising from leadership changes, (xii) legislative, regulatory and economic developments, and (xiii) the other risks described in Globus
Medicals and NuVasives most recent annual reports on Form 10-K and quarterly reports on Form 10-Q.